Fritextsökning
Artiklar per år
Innehållstyper
-
ALS – When the body has given up, but the brain persists
The nerve disease ALS gradually deprives the patient of control over the muscles and, eventually, also of speech. The eyes continue to function, though, and with the help of, among other things, a Swedish-developed invention, communication with the outside world can continue. “It’s their window to the world,” says ALS researcher Caroline Ingre.
-
“Photon counting in computed tomography is the holy grail”
Erik Fredenberg, a researcher in physics at KTH and GE, is working to implement photon-counting CT in clinics. To shorten lead times and reduce the radiation dose in patients, he is setting out to develop a framework for virtual clinical trials
-
She creates pharmaceuticals on a 3D printer
The correct dosage for each individual, regardless of whether the pharmaceutical is for a seriously ill child or a frail elderly person, is the mission of a well-advanced project with 3D-printed drugs at Uppsala University. “It will soon be available in clinics”, says Christel Bergström, who is heading the project.
-
The stomach medication that became the biggest blockbuster of the 1990s
The omeprazole molecule was synthesised as early as 1979, but it took many years before the then Astra had an approved pharmaceutical. Once this happened, a tablet was available that was soon to help millions of people worldwide and break all sales records.
-
He is zooming in on topical preparations
According to Zelmic CEO David Sagna, topical products in drug development is a growing market, and to keep pace with the development, the company is awaiting approval for its new GMP facility.
-
Behandling som skjuter upp diabetes typ 1 godkänd i USA – "Historiskt ögonblick"
Den amerikanska läkemedelsmyndigheten FDA har godkänt en behandling som fördröjer utbrottet av typ 1-diabetes, och därmed kan bespara patienter åratal av insulinsprutor, blodsockerkontroller och hård diet.
-
Swedish breakthrough in Alzheimer’s: “We can finally present great data”
Treatments for Alzheimer’s disease are currently among the hottest topics in drug development. Two Swedish research companies with high ambitions and successes in the field participated in Bioscience 2022 conference at Life City in Hagastaden, Stockholm.
-
Neanderthal genes and Nobel Prize in a popular lecture at Bioscience
An inherited gene variant from our ”evolutionary cousins” – the extinct Neanderthals – may affect how our bodies break down certain drugs. “It’s only a matter of time before we actively start screening for it,” said KI researcher Hugo Zeberg when
-
"Are we doing business the wrong way around in the Life Science Sector?"
For the past 50 years we have created solutions for problems that we thought would solve the problems. Pharmaceuticals have created big block buster drugs which were great for that time but now we realise that these drugs were in fact only tested
-
A green nursery for biotech rooted in the Scanian soil
Red Glead has established itself as one of Lund’s largest companies in pharmaceutical development. Life Science Sweden went to Skåne and met two of the founders, Johan Evenäs and Martina Kvist Reimer.
-
“We need to build flexible operating theatres”
Flexible operating theatres, micro-sensors on surgeons to monitor their well-being and 3D images projected onto organs to be operated on. These are a few ideas that three specialist surgeons are suggesting for the operating theatre of the future.
-
EU:s inköp av covidvaccin utreds av åklagare
Europeiska åklagarmyndigheten, Eppo, har inlett en utredning om misstänkta oegentligheter i samband med affärer med covid-19-vaccin inom EU. Flera internationella medier kopplar uppgifterna till ifrågasatta kontakter mellan Pfizers ledning och EU-toppen Ursula von der Leyen.
-
“We aim to be a start-up company with an academic spirit”
Chronic pain and Alzheimer’s are two diseases that plague many people worldwide and seem impossible to cure. However, Huddinge-based company Alzecure is working on developing drugs for both conditions.
-
66 barn misstänks ha dött av hostmedicin – WHO utfärdar varning
WHO varnar för fyra sorters hostmedicin från det indiska läkemedelsbolaget Maiden Pharmaceuticals, vars medicin tros ha orsakat 66 barns död i Gambia.
-
“We need to keep investing in research and innovation”
Jenni Nordborg has worked for just over four years to highlight life science in Sweden. Her mandate as national coordinator ends in December 2022. ““Life sciences has been a long-term priority of governments since many years and I have no doubt that the ambitions will be strong going forward”, says Jenni Nordborg.
-
Biosimilars bring price pressure, but are they sufficiently used?
When biosimilars were introduced just over 16 years ago, hopes were raised that they would give many more patients access to effective but otherwise extremely expensive treatments with biological drugs. So, how well has Swedish healthcare used biosimilars? The answer partly depends on whom you ask.
-
Nytt coronavirus upptäckt hos fladdermöss – tog sig förbi vaccin
Ett nytt coronavirus i levande fladdermöss har upptäckts av forskare i USA. Enligt forskarna är viruset resistent mot befintliga covidvaccin.
-
Bought a tablet factory – and built his own empire
In 1995, Thomas Eldered was CEO of one of Pharmacia’s factories in the Stockholm area when the Swedish pharmaceutical giant, after a takeover, decided to move its production abroad. 34-year-old Thomas was facing an imminent risk of losing his job. However, instead, it actually turned out to be the starting point for one of the biggest success stories in Swedish life science.
-
Life Science-podden: The perfect moment for an IPO
When is the right time to go for an IPO? What strategy is recommended in today´s rather uncertain business climate when it comes to taking your life science company public?
-
Swedish-Danish meeting at Medicon Village: “One of the most important life science congresses”
For the eleventh year, The Future of Swedish and Danish Life Science was held on Wednesday, and the event continues to function as a connecting link between the life science sectors of both countries. This year’s event attracted nearly 450 visitors.
-
Anders Blanck about his 17 years at Lif: “The industry is enjoying greater public trust now"
The announcement came as a surprise to those around him, but according to the protagonist himself, the timing was excellent. Anders Blanck is now leaving Lif – a decision that has been growing for some time. “I have been pretty much married to my mission
-
Sweden is heavily criticised for not ordering Covid vaccine
Valneva and the EU Commission have entered into an agreement for 1.25 million doses of the company’s Covid vaccine, but Sweden has not placed an order.
-
Amorphous materials take centre stage when Orexo develops new formulations
Swift resolution but with maintained stability. Orexo’s new drug delivery platform tackles the problem of amorphous materials. “Our technology has the positive properties of the material, and it also cracks some of the problems,” says the company’s Research and Development Manager Robert Rönn.
-
BioVentureHub CEO: “Companies with a high degree of interaction achieve greater success”
For the first time since its inception, AstraZeneca’s BioVentureHub can now recruit new companies, as some of its tenants have grown significantly and are leaving the hub. This is the message from the biohub’s CEO Magnus Björsne in an interview, in which
BREAKING